Stage at diagnosis and breast cancer-specific mortality in breast cancer patients treated with antidepressants, anxiolytics, and antipsychotics: a population-based cohort study from Northern Ireland
Authors:
Open Access
- 5 July 2025
- journal article
- research article
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 213 (1) , 137-150
Abstract
Purpose: We examined the stage at diagnosis and breast cancer-specific mortality in a cohort of breast cancer patients prescribed medications used for mental health conditions before diagnosis. Methods: Women newly diagnosed with breast cancer from 2011 to 2021 were identified from the Northern Ireland Cancer Registry. The primary outcome was time to breast cancer-specific mortality up to March 2023. The secondary outcomes included stage at diagnosis. We identified anxiolytic, antidepressant, and antipsychotic prescriptions dispensed in the year before breast cancer diagnosis from the Northern Ireland Enhanced Prescribing Database. Cox regression models were used to calculate adjusted hazard ratios (aHR) and 95% confidence intervals (95%CIs) for cancer-specific mortality by use of medications. Results: We included 13,846 women with breast cancer. In the year before breast cancer diagnosis, 31.5% were dispensed antidepressants, 12.7% anxiolytics, and 3.5% antipsychotics. The odds of late-stage disease presentation in breast cancer patients dispensed medications for mental health conditions was similar to breast cancer patients not dispensed these medications, but patients dispensed antipsychotics had higher odds of unknown stage. We found no difference in the hazard rate of breast cancer-specific mortality in patients dispensed, versus not dispensed, anxiolytics (aHR = 1.06 95%CI 0.93–1.20), a small increase in patients dispensed, versus not dispensed, antidepressants (aHR = 1.11 95%CI 1.01–1.23) and a moderate increase in patients dispensed, versus not dispensed, antipsychotics (aHR = 1.45 95%CI 1.17–1.81). Conclusions: Breast cancer patients dispensed medications for mental health conditions were not at higher odds of presenting with late-stage disease, but patients dispensed antidepressants, and especially antipsychotics, had worse breast cancer-specific mortality.Keywords
This publication has 47 references indexed in Scilit:
- Barriers and facilitators for people with severe mental illness accessing cancer screening: A systematic reviewPsycho-Oncology, 2024
- Barriers in cancer trajectories of patients with pre‐existing severe mental disorders—A systematic reviewPsycho-Oncology, 2023
- Influence of depression on breast cancer treatment and survival: A Kentucky population‐based studyCancer, 2023
- Impact of preexisting mental illness on breast cancer endocrine therapy adherenceBreast Cancer Research and Treatment, 2018
- Prevalence, incidence, indication, and choice of antidepressants in patients with and without chronic kidney disease: a matched cohort study in UK Clinical Practice Research DatalinkPharmacoepidemiology and Drug Safety, 2017
- Effect of depression before breast cancer diagnosis on mortality among postmenopausal womenCancer, 2017
- Treatment Indications for Antidepressants Prescribed in Primary Care in Quebec, Canada, 2006-2015JAMA, 2016
- The association of mood disorders with breast cancer survival: an investigation of linked cancer registration and hospital admission data for South East EnglandPsycho-Oncology, 2015
- Cancer-Related Mortality in People With Mental IllnessJAMA Psychiatry, 2013
- Imputing missing covariate values for the Cox modelStatistics in Medicine, 2009